One sample, two tests: TB and COVID-19 together

Diagnosing respiratory infections often means collecting separate samples and running different laboratory workflows for each pathogen. That can be time-consuming, expensive, and hard to manage in clinics with limited capacity. To address this, a research team led by Padmapriya P. Banada worked on simplifying the front end of testing by focusing on the extraction step that prepares genetic material for analysis. Their effort concentrated on respiratory samples and on extracting total nucleic acids so that the same material could be used to look for both Mycobacterium tuberculosis and SARS-CoV-2. By pulling DNA and RNA out of a single specimen in one streamlined step, the approach aims to make it easier for labs to test for these two major respiratory threats without needing duplicate collections or separate extraction protocols. The project emphasizes compatibility across diagnostic platforms so that the extracted material can be applied to a variety of downstream tests that laboratories already use.

The core technical idea reported in the abstract is a simplified co-extraction of total nucleic acids from respiratory samples. Total nucleic acids refers to the combined genetic material (both RNA and DNA) needed to detect a range of pathogens, and the researchers designed the extraction to be compatible with multiple diagnostic platforms. The abstract states the method is optimized so that the same extracted material can be used for detection of Mycobacterium tuberculosis and for detection of SARS-CoV-2 from a single sample. Although the abstract does not list specific instruments, reagents, or quantitative results, it highlights that the method targets total nucleic acids and was developed with cross-platform compatibility in mind. That means laboratories using different molecular tests could, in principle, accept the extract and proceed with their established assays for either pathogen without separate extraction steps.

If the simplified co-extraction works as intended, it could change routine testing workflows by reducing the number of samples needed from patients and consolidating laboratory steps. That could save time, reduce supply needs, and lower the burden on staff who must manage multiple procedures for TB and COVID-19 testing. For public health, having one extract that feeds into multiple diagnostic platforms could improve surveillance and case finding when both pathogens are a concern, and it could make combined testing more feasible in low-resource settings. The approach also has practical implications for patient comfort and sample logistics: a single collection is easier on patients and simpler to store and transport. The abstract frames this work as an optimization for broad compatibility, suggesting the next steps would be to validate performance and integrate the co-extraction into existing diagnostic workflows so that laboratories can adopt it alongside their current tests.